R. P. Scherer
Capsule maker completes the acquisition of Polysystems Ltd., a U.K.-based drug delivery R&D firm. Polysystems has an exclusive option on the worldwide rights to Pulsincap, a water-soluble capsule designed to release a drug in the gastrointestinal tract at a given time. R. P. Scherer says the technology "provides an important extension" to the existing rapidly developing drug delivery business of R. P. Scherer, based on the patented Scheresol softgel systems and the Zydis fast-dissolving dosage form.
You may also be interested in...
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.